In a report released on May 11, Thomas Smith from SVB Securities reiterated a Hold rating on Immunic (IMUX – Research Report), with a price target of $5.00. The company’s shares closed last Friday at $1.74.
Smith covers the Healthcare sector, focusing on stocks such as Immunic, Dice Therapeutics, and Celldex. According to TipRanks, Smith has an average return of 39.8% and a 49.54% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Immunic with a $12.67 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $11.76 and a one-year low of $1.11. Currently, Immunic has an average volume of 1.25M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Immunic, Inc. engages in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.
Read More on IMUX:
- Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update
- IMUX Earnings this Week: How Will it Perform?
- Immunic management to meet with Piper Sandler
- IMUX Soars on Promising Data in Ulcerative Colitis
- Immunic reports CALDOSE-1 trial data, to deprioritize izumerogant development
